Материалы доступны только для специалистов сферы здравоохранения. Авторизуйтесь или зарегистрируйтесь.
Лечение эректильной дисфункции: эффекты силденафила
Лечение эректильной дисфункции: эффекты силденафила
Верткин А.Л., Моргунов Л.Ю. Лечение эректильной дисфункции: эффекты силденафила. Consilium Medicum. 2014; 16 (2): 63–66.
Материалы доступны только для специалистов сферы здравоохранения. Авторизуйтесь или зарегистрируйтесь.
Полный текст
Список литературы
1. Ayta IA, McKinlay JB, Krane RJ. The likely worldwide increase in erectile dysfunction between 1995 and 2025 and some possible policy consequences. BJU Int 1999; 84 (1): 50–6.
2. Wagner G, Fugl-Meyer KS, Fugl-Meyer AR. Impact of erectile dysfunction on quality of life: patient and partner perspectives. Int J Impot Res 2000; 4 (S1): 44–6.
3. Corona G, Mondaini N, Ungar A et al. Phosphodiesterase type 5 (PDE5) inhibitors in erectile dysfunction: the proper drug for the proper patient. J Sex Med 2011; 8 (12): 3418–32.
4. Gresser U, Gleiter CH. Erectile dysfunction: comparison of efficacy and side effects of the PDE-5 inhibitors sildenafil, vardenafil, and tadalafil review of the literature. Eur J Med Res 2002; 7: 435–46.
5. McCullough AR. Four-year review of sildenafil citrate. Rev Urol 2002; 4 (Suppl. 3): S26–38.
6. Carson CC. Sildenafil: a 4-yearupdate in the treatment of 20 million erectile dysfunction patients. Curr Urol Rep 2003; 4 (6): 488–96.
7. Brown M, Prisant LM, Collins M. Effect of sildenafil in patients with erectile dysfunction takin antihypertensive therapy. Am J Hematol 2001; 14: 70–3.
8. Sunwoo S, Kim YS, Cho BL et al. Post-marketing surveillance study of the safety and efficacy of sildenafil prescribed in primary care to erectile dysfunction patients. Int J Impot Res. 2005; 17 (1): 71–5.
9. Rashid A. The efficacy and safety of PDE5 inhibitors. Clin Cornerstone 2005; 7 (1): 47–56.
10. Taylor J et al. Differences in side-effect duration and related bother levels between phosphodiesterase type 5 inhibitors. BJU Int 2009; 103: 1392–5.
11. Leslie SJ et al. No adverse hemodynamic interaction between sildenafil and red wine. Clin Pharmacol Ther 2004; 76: 365–70.
12. Kennedy SH, Dugre H, Defoy I. A multicenter, double-blind, placebo-controlled study of sildenafil citrate in Canadian men with erectile dysfunction and untreated symptoms of depression, in the absence of major depressive disorder. Int Clin Psychopharmacol 2011; 26 (3): 151–8.
13. Dording CM, LaRocca RA, Hails KA et al. The effect of sildenafil on quality of life. Ann Clin Psychiatry 2013; 25 (1): 3–10.
14. Abolyosr A, Elsagheer GA, Abdel-Kader MS et al. Evaluation of the effect of sildenafil and/or doxazosin on Benign prostatic hyperplasia-related lower urinary tract symptoms and erectile dysfunction. Urol Ann 2013; 5 (4): 237–40.
15. Cui H, Liu B, Song Z et al. Efficacy and safety of long-term tadalafil 5 mg once daily combined with sildenafil 50 mg as needed at the early stage of treatment for patients with erectile dysfunction. Andrologia 2014 Jan 6; doi: 10.1111/and.12216.
16. Spitzer M, Bhasin S, Travison TG et al. Sildenafil increases serum testosterone levels by a direct action on the testes. Andrology 2013; 1 (6): 913–8.
17. Buvat J, Hatzichristou D, Maggi M et al. Efficacy, tolerability and satisfaction with sildenafil citrate 100-mg titration compared with continued 50-mg dose treatment in men with erectile dysfunction. BJU Int 2008; 102 (11): 1645–50.
2. Wagner G, Fugl-Meyer KS, Fugl-Meyer AR. Impact of erectile dysfunction on quality of life: patient and partner perspectives. Int J Impot Res 2000; 4 (S1): 44–6.
3. Corona G, Mondaini N, Ungar A et al. Phosphodiesterase type 5 (PDE5) inhibitors in erectile dysfunction: the proper drug for the proper patient. J Sex Med 2011; 8 (12): 3418–32.
4. Gresser U, Gleiter CH. Erectile dysfunction: comparison of efficacy and side effects of the PDE-5 inhibitors sildenafil, vardenafil, and tadalafil review of the literature. Eur J Med Res 2002; 7: 435–46.
5. McCullough AR. Four-year review of sildenafil citrate. Rev Urol 2002; 4 (Suppl. 3): S26–38.
6. Carson CC. Sildenafil: a 4-yearupdate in the treatment of 20 million erectile dysfunction patients. Curr Urol Rep 2003; 4 (6): 488–96.
7. Brown M, Prisant LM, Collins M. Effect of sildenafil in patients with erectile dysfunction takin antihypertensive therapy. Am J Hematol 2001; 14: 70–3.
8. Sunwoo S, Kim YS, Cho BL et al. Post-marketing surveillance study of the safety and efficacy of sildenafil prescribed in primary care to erectile dysfunction patients. Int J Impot Res. 2005; 17 (1): 71–5.
9. Rashid A. The efficacy and safety of PDE5 inhibitors. Clin Cornerstone 2005; 7 (1): 47–56.
10. Taylor J et al. Differences in side-effect duration and related bother levels between phosphodiesterase type 5 inhibitors. BJU Int 2009; 103: 1392–5.
11. Leslie SJ et al. No adverse hemodynamic interaction between sildenafil and red wine. Clin Pharmacol Ther 2004; 76: 365–70.
12. Kennedy SH, Dugre H, Defoy I. A multicenter, double-blind, placebo-controlled study of sildenafil citrate in Canadian men with erectile dysfunction and untreated symptoms of depression, in the absence of major depressive disorder. Int Clin Psychopharmacol 2011; 26 (3): 151–8.
13. Dording CM, LaRocca RA, Hails KA et al. The effect of sildenafil on quality of life. Ann Clin Psychiatry 2013; 25 (1): 3–10.
14. Abolyosr A, Elsagheer GA, Abdel-Kader MS et al. Evaluation of the effect of sildenafil and/or doxazosin on Benign prostatic hyperplasia-related lower urinary tract symptoms and erectile dysfunction. Urol Ann 2013; 5 (4): 237–40.
15. Cui H, Liu B, Song Z et al. Efficacy and safety of long-term tadalafil 5 mg once daily combined with sildenafil 50 mg as needed at the early stage of treatment for patients with erectile dysfunction. Andrologia 2014 Jan 6; doi: 10.1111/and.12216.
16. Spitzer M, Bhasin S, Travison TG et al. Sildenafil increases serum testosterone levels by a direct action on the testes. Andrology 2013; 1 (6): 913–8.
17. Buvat J, Hatzichristou D, Maggi M et al. Efficacy, tolerability and satisfaction with sildenafil citrate 100-mg titration compared with continued 50-mg dose treatment in men with erectile dysfunction. BJU Int 2008; 102 (11): 1645–50.
Авторы
А.Л.Верткин, Л.Ю.Моргунов
ГБОУ ВПО МГМСУ им. А.И.Евдокимова Минздрава России
ГБОУ ВПО МГМСУ им. А.И.Евдокимова Минздрава России
Цель портала OmniDoctor – предоставление профессиональной информации врачам, провизорам и фармацевтам.